Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in AQP4-IgG Positive NMOSD
NCT05284175Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of orelabrutinib in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Annualized Relapse Rate at 48 weeks. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05284175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284175.